The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and children aged 9 years and older.

A new combination therapy that pairs a radiopharmaceutical (177Lu-DOTATATE) with a DNA-repair blocker (olaparib) has been ...

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

Clearance of ASC50 paves the way for a Phase I trial in patients with mild-to-moderate plaque psoriasis.

Margrit Wiesendanger, MD, PhD, discusses how lupus treatment is evolving from traditional therapies to more targeted options like biologics, with promising advances now being explored in clinical ...

Guselkumab treatment was associated with improvements in 3 biomarkers associated with systemic inflammation among patients with plaque psoriasis.

Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for a Phase I trial for ASC50 for the ...

U.S. prices for newly-launched pharmaceuticals more than doubled last year compared to 2021, as companies leveraged ...

Let’s discuss four foods to avoid with psoriasis that may be affecting your skin, along with healthier substitutes.

By elevating patient perspectives from an afterthought to a core part of the process, payers can create a system that aligns ...

Pyzchiva® is a key biosimilar value driver for the Sandoz growth strategy. It has been launched in 23 markets in Europe. The autoinjector is now available in Spain and will continue to roll out across ...

A new study published in the journal of Acta Dermato Venerologica showed that menopause might have neutral to negative impact ...